Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E19.12 EPS (ttm)3.34 Insider Own0.10% Shs Outstand1.62B Perf Week0.77%
Market Cap103.33B Forward P/E11.37 EPS next Y5.61 Insider Trans-26.69% Shs Float1.62B Perf Month6.59%
Income5.48B PEG1.18 EPS next Q1.20 Inst Own71.00% Short Float4.40% Perf Quarter4.80%
Sales23.78B P/S4.35 EPS this Y185.20% Inst Trans-0.01% Short Ratio7.73 Perf Half Y10.47%
Book/sh2.87 P/B22.23 EPS next Y18.13% ROA10.20% Target Price70.17 Perf Year-6.02%
Cash/sh5.31 P/C12.02 EPS next 5Y16.19% ROE115.60% 52W Range44.16 - 68.85 Perf YTD10.86%
Dividend2.28 P/FCF24.97 EPS past 5Y3.50% ROI16.90% 52W High-7.32% Beta1.48
Dividend %3.57% Quick Ratio1.40 Sales past 5Y7.90% Gross Margin79.80% 52W Low44.49% ATR1.09
Employees28000 Current Ratio1.60 Sales Q/Q18.20% Oper. Margin34.20% RSI (14)59.60 Volatility1.07% 1.73%
OptionableYes Debt/Eq6.87 EPS Q/Q31.10% Profit Margin23.00% Rel Volume0.54 Prev Close63.89
ShortableYes LT Debt/Eq6.35 EarningsJul 29 BMO Payout64.30% Avg Volume9.20M Price63.81
Recom2.30 SMA202.27% SMA503.80% SMA20010.98% Volume4,972,650 Change-0.13%
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Jul-24-16 02:06PM  5 Reasons Biotech Stocks Are Smart Investments at Motley Fool
Jul-22-16 04:44PM  5 Big Drugmakers Reporting Earnings Next Week
11:33AM  Biogen Inc: How Double-Digit Growth Got Trumped at Motley Fool
Jul-21-16 10:02AM  Biogen: CEO Departing; Is This Drug Maker In Play? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
09:03AM  These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying? at Motley Fool
08:40AM  Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
08:00AM  How Abbvie's Humira Undercuts The Drug Industry Price Defense at Forbes
Jul-20-16 03:36PM  Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
09:44AM  These new drugs might never get a chance to save the U.S. $250 billion at MarketWatch
Jul-19-16 11:35AM  Gilead Sciences: There Will Be Disappointment at Barrons.com
10:37AM  A Four-Stock 4% Dividend Growth Portfolio at Forbes
Jul-18-16 10:04AM  Is This Gilead Sciences' Most Underappreciated Drug Candidate? at Motley Fool
Jul-16-16 09:15AM  Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now at 24/7 Wall St.
Jul-15-16 05:29PM  Two of the Worlds Best-Selling Drugs Are Headed for a Lot More Competition at Fortune
Jul-14-16 04:22PM  3 Big Pharma Stocks That Could Raise Their Dividends at Motley Fool
01:15PM  3 Dividend Aristocrats to Avoid at Motley Fool
11:56AM  Could the Dow Jump Up Another 400 Points By Year's End?
09:30AM  The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
04:48AM  [$$] Biosimilars set topple two of the world's biggest drug franchises at Financial Times
Jul-13-16 03:17PM  Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
12:39PM  Why Amgens positive biosimilar news isnt as good as it seems at MarketWatch
12:14PM  AbbVie, Inc. : ABBV-US: Dividend Analysis : July 15th, 2016 (record date) : By the numbers : July 13, 2016
09:15AM  Short Sellers Run for Cover From Major Pharma at 24/7 Wall St.
07:38AM  [$$] Road to Launching 'Biosimilar' Drugs Just Got Longer at The Wall Street Journal
07:30AM  [$$] Gormley's Take: Road to Launching 'Biosimilar' Drugs Just Got Longer at The Wall Street Journal
07:27AM  [$$] A Threat to Biotechs, but a Slow-Motion One at The Wall Street Journal
Jul-12-16 09:06PM  Regenerons Robust Pipeline
05:49PM  FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
04:59PM  Amgen Moves Closer to Selling Competitor for AbbVies Humira at Bloomberg
04:32PM  U.S. FDA panel backs Amgen copy of AbbVie arthritis drug Humira Reuters
01:49PM  [$$] A Threat to Biotechs, but a Slow-Motion One at The Wall Street Journal
10:19AM  AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
10:07AM  Rova-T and Immuno-Oncology Therapies May Be Complementary
05:29AM  Shires Shares Rise on FDA Approval of Dry Eye Med
Jul-11-16 03:13PM  Why AbbVies Rova-T May Have More Growth Potential than Predicted
03:13PM  Why Is AbbVies Valuation Multiple Rising in July?
11:37AM  UPDATE 2-Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
09:39AM  AbbVie Gets FDA Rare Pediatric Disease Designation For Investigational ABT-414
08:13AM  Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
08:04AM  Amgen Humira Biosimilar Briefing Documents Look Good
08:00AM  AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) PR Newswire
Jul-10-16 03:04AM  Why AbbVie Expects Rova-T to See Big Peak Sales
Jul-08-16 04:19PM  Amgen's Biosimilar Humira Gets FDA Support Ahead Of Panel
02:37PM  Reading market tea leaves
12:40PM  Amgen drug appears 'highly similar' to Humira -FDA staff Reuters
09:05AM  Inside AbbVies Plans to Target Multiple Myeloma and Acute Myeloid Leukemia Segments with Venclexta
08:12AM  FDA staff say Amgen biosimilar "highly similar" to Abbvie's Humira
Jul-07-16 11:05AM  Behind AbbVies Aggressive Exploration of Venclexta for Multiple Indications
03:00AM  AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress PR Newswire
Jul-06-16 12:13PM  AbbVie Is Poised to Move Even Higher
11:11AM  AbbVie Requires An Extraordinary Rescue; What Are The Options? at Forbes
11:05AM  Imbruvica May Become a Key Therapy for Follicular Lymphoma
09:48AM  Biogen, AbbVie: How Significant is the New MS Drug Zinbryta
09:05AM  Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
Jul-05-16 04:27PM  How Gilead's New Hepatitis C Virus Combination Stacks Up to the Competition at Motley Fool
04:21PM  Insys Stock Jumps As FDA Approves Appetite-Boosting Cannabis Drug
01:10PM  Abbott deal for St. Jude spurs company split talk
11:05AM  AbbVies Tests of Imbruvica with Venclexta for Oncology Therapy
10:06AM  Behind AbbVies Imbruvica: A Comprehensive Development Program for Treatment
09:21AM  Biogen And AbbVie's Once-Monthly ZINBRYTA Gets European Union Approval For Multiple Sclerosis Treatment
09:05AM  Could AbbVies Imbruvica Become a Key Growth Driver in 2016?
08:00AM  Biogen and AbbVies Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis Business Wire
Jul-04-16 09:05AM  What Could Happen with AbbVies EFNA4-Calicheamicin in Cancer Stem-Cell Therapy?
Jul-03-16 07:38AM  How Major Pharma Is Faring After the Brexit at 24/7 Wall St.
06:40AM  The Big Loser After Gilead's Latest Approval May Not Be Who You Think (Hint: It's not AbbVie, Inc.) at Motley Fool
Jul-01-16 03:40PM  An Overnight Double! Could These Drugmakers Be Next? at Motley Fool
12:07PM  Understanding Pfizers Growth Contributors
11:06AM  Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
10:06AM  Understanding Trinity: Inside the Testing of AbbVies Rova-T
09:30AM  Owens-Illinois, Korn Ferry, AbbVie and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
09:04AM  AbbVie Humira Gains FDA Approval for Yet Another Indication
08:34AM  OraSure's stock drops after co-promotion pact with AbbVie ends early at MarketWatch
08:00AM  AbbVie to Host Second-Quarter Earnings Conference Call PR Newswire
06:50AM  What's working: Best sector bets
Jun-30-16 08:26PM  AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis PR Newswire
11:06AM  Inside the Unique Mechanism of AbbVies Rova-T for Treating Small-Cell Lung Cancer
09:38AM  AbbVie, J&J's Imbruvica Gets Breakthrough Therapy Status
09:30AM  The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
09:06AM  Could Rova-T Become AbbVies Blockbuster Therapy for Small Cell Lung Cancer?
08:08AM  3 Dividend Growth Stocks to Buy in July at Motley Fool
08:06AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : June 30, 2016
Jun-29-16 02:35PM  Top 6 Research Reports for June 29, 2016
02:23PM  Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
11:25AM  2016s Top 10 Dividend Stocks at Motley Fool
11:08AM  Infinity Regains Duvelisib Rights, Announces Restructuring
10:07AM  Can Stemcentrxs Cancer Stem Cell Technology Really Accelerate Innovation for AbbVie?
09:15AM  Finding Reliable 3%+ Dividends in Todays Market: AbbVie Inc (ABBV) at Insider Monkey
09:11AM  AbbVie Gets Fourth Breakthrough Therapy Designation From FDA For ibrutinib
09:00AM  Research Report Initiated on Select Major Drug Manufacturers Equities
07:30AM  AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options PR Newswire
Jun-28-16 06:40PM  The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What? at Motley Fool
04:24PM  Think Healthcare M&A Is Dead? Think Again. at Motley Fool
11:50AM  Gilead HCV Pill Approved For Broad Usage, Priced Below Sovaldi
11:07AM  Inside AbbVies Analyst Recommendations in 2016
11:04AM  Why Is AbbVie Witnessing a Gradual Rise in Valuations in 2016?
10:13AM  Credit Suisse Sees 'Reasons For Optimism' On AbbVie at Barrons.com
09:40AM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
Jun-27-16 11:45PM  Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? at Motley Fool
04:02PM  Better Buy: Merck & Co. Inc. vs. AbbVie at Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM